Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels
about
The Sur1-Trpm4 Channel in Spinal Cord InjuryCardiovascular impact of drugs used in the treatment of diabetesEndothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury.Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.Altered potassium ATP channel signaling in mesenteric arteries of old high salt-fed rats.Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells.The life and death of breast cancer cells: proposing a role for the effects of phytoestrogens on potassium channels.Variations in tissue selectivity amongst insulin secretagogues: a systematic review.Repaglinide: a review of its use in type 2 diabetes mellitus.Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes.Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus.Incomplete dissociation of glibenclamide from wild-type and mutant pancreatic K ATP channels limits their recovery from inhibition.Analysis of two KCNJ11 neonatal diabetes mutations, V59G and V59A, and the analogous KCNJ8 I60G substitution: differences between the channel subtypes formed with SUR1.Optogenetic regulation of insulin secretion in pancreatic β-cells.Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K(ATP) channel.From in silico to in vitro: a trip to reveal flavonoid binding on the Rattus norvegicus Kir6.1 ATP-sensitive inward rectifier potassium channel.
P2860
Q33602457-65D0CE1E-BBD5-4140-8E79-CFFA2E56C08CQ34383575-EF88824D-4013-444F-B2FC-2F09F1758945Q35901019-49A4A610-F479-4CE9-BB86-4118EE0C8ADEQ36868364-32CBEC43-BCB1-4687-A208-F8EDD74F80BAQ37160817-60350F86-5E82-4464-9A75-066FFBC6AAACQ37571935-99987DEA-6963-472C-AE67-6F13A11B76E3Q37897500-5CEB96D3-96E5-4870-A515-F880BFCD8C4FQ37933466-9DD98D83-A2D0-4DC4-A528-D47A7E2BC560Q37977979-5BBE404E-7916-4FD8-A4BE-3B263704750CQ38073629-6CBD9AC7-798B-4B71-BA83-863BD4EE7937Q38184608-0CD02F6A-4DB1-4FB0-9E62-AA92268B445BQ39893357-D62D4FD5-801A-4432-84D9-CA8C81AA889EQ39896293-D6E683F0-AEA8-4F8C-A644-5E77294EA2BAQ41518152-62C9A88C-EC54-4861-83C8-4C165F40C47DQ52618285-DA803555-4F36-4817-B58F-6388A0665022Q55087147-765514AD-2E51-4873-B53A-D8D59ED35BE5
P2860
Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Selectivity of repaglinide and ...... cardiovascular K(ATP) channels
@ast
Selectivity of repaglinide and ...... cardiovascular K(ATP) channels
@en
Selectivity of repaglinide and ...... cardiovascular K(ATP) channels
@nl
type
label
Selectivity of repaglinide and ...... cardiovascular K(ATP) channels
@ast
Selectivity of repaglinide and ...... cardiovascular K(ATP) channels
@en
Selectivity of repaglinide and ...... cardiovascular K(ATP) channels
@nl
prefLabel
Selectivity of repaglinide and ...... cardiovascular K(ATP) channels
@ast
Selectivity of repaglinide and ...... cardiovascular K(ATP) channels
@en
Selectivity of repaglinide and ...... cardiovascular K(ATP) channels
@nl
P2093
P2860
P3181
P1433
P1476
Selectivity of repaglinide and ...... cardiovascular K(ATP) channels
@en
P2093
P2860
P2888
P304
P3181
P356
10.1007/S00125-006-0307-3
P407
P577
2006-09-01T00:00:00Z
P5875
P6179
1011114225